title: Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa.
abstract: Two-thirds of the world's HIV-infected people live in sub-Saharan Africa, and more than 1.5 million of them die annually. As access to antiretroviral treatment has expanded within the region; early pessimism concerning the delivery of antiretroviral treatment using a large-scale public health approach has, at least in the short term, proved to be broadly unfounded. Immunological and virological responses to ART are similar to responses in patients treated in high-income countries. Despite this, however, early mortality rates in sub-Saharan Africa are very high; between 8 and 26% of patients die in the first year of antiretroviral treatment, with most deaths occurring in the first few months. Patients typically access antiretroviral treatment with advanced symptomatic disease, and mortality is strongly associated with baseline CD4 cell count less than 50 cells/mul and WHO stage 4 disease (AIDS). Although data are limited, leading causes of death appear to be tuberculosis, acute sepsis, cryptococcal meningitis, malignancy and wasting syndrome. Mortality rates are likely to depend not only on the care delivered by antiretroviral treatment programmes, but more fundamentally on how advanced disease is at programme enrollment and the quality of preceding healthcare. In addition to improving delivery of antiretroviral treatment and providing it free of charge to the patient, strategies to reduce mortality must include earlier diagnosis of HIV infection, strengthening of longitudinal HIV care and timely initiation of antiretroviral treatment. Health systems delays in antiretroviral treatment initiation must be minimized, especially in patients who present with advanced immunodeficiency.
authors.forename: Stephen D
authors.initials: SD
authors.lastname: Lawn
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Harries
authors.forename: Xavier
authors.initials: X
authors.lastname: Anglaret
authors.forename: Landon
authors.initials: L
authors.lastname: Myer
authors.forename: Robin
authors.initials: R
authors.lastname: Wood
mesh_terms: D017954:Africa South of the Sahara / Q000453:epidemiology; D023241:Antiretroviral Therapy, Highly Active; D002423:Cause of Death; D003695:Delivery of Health Care / Q000458:organization & administration; D042241:Early Diagnosis; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D012307:Risk Factors
references.citation: Lancet. 2006 Jun 17;367(9527):1981-9
references.pmid: 16782488
references.citation: Lancet. 2002 Jul 13;360(9327):119-29
references.pmid: 12126821
references.citation: Arch Intern Med. 2008 Jan 14;168(1):86-93
references.pmid: 18195200
references.citation: Lancet. 2006 Mar 11;367(9513):817-24
references.pmid: 16530575
references.citation: N Engl J Med. 2006 Sep 14;355(11):1141-53
references.pmid: 16971720
references.citation: Clin Infect Dis. 2006 Sep 15;43(6):770-6
references.pmid: 16912954
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Lancet. 2003 Jul 5;362(9377):22-9
references.pmid: 12853195
references.citation: IAPAC Mon. 2002 Jun;8(6):168-75
references.pmid: 12154788
references.citation: AIDS. 2007 Jul 11;21(11):1441-8
references.pmid: 17589190
references.citation: J Infect Dis. 2007 Aug 15;196 Suppl 1:S52-62
references.pmid: 17624827
references.citation: BMC Infect Dis. 2006 Mar 21;6:59
references.pmid: 16551345
references.citation: Int J Tuberc Lung Dis. 2007 Aug;11(8):848-53
references.pmid: 17705949
references.citation: Clin Infect Dis. 2006 Oct 15;43(8):1069-73
references.pmid: 16983622
references.citation: Clin Infect Dis. 2005 Jul 15;41(2):217-24
references.pmid: 15983918
references.citation: S Afr Med J. 2006 Apr;96(4):315-20
references.pmid: 16670804
references.citation: Bull World Health Organ. 2007 Jul;85(7):550-4
references.pmid: 17768504
references.citation: Antivir Ther. 2007;12(5):753-60
references.pmid: 17713158
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jan 1;14(1):83-5
references.pmid: 8989219
references.citation: Int J Tuberc Lung Dis. 2007 Apr;11(4):412-6
references.pmid: 17394687
references.citation: AIDS. 2003 Jul;17 Suppl 3:S5-15
references.pmid: 14565604
references.citation: AIDS. 2006 May 12;20(8):1181-9
references.pmid: 16691070
references.citation: PLoS Med. 2007 Oct 16;4(10):e298
references.pmid: 17941716
references.citation: Clin Infect Dis. 2002 Dec 15;35(12):e128-33
references.pmid: 12471589
references.citation: Trop Med Int Health. 2007 Aug;12(8):929-35
references.pmid: 17697087
references.citation: N Engl J Med. 1998 Mar 26;338(13):853-60
references.pmid: 9516219
references.citation: AIDS. 2005 Nov 18;19(17):2050-2
references.pmid: 16260920
references.citation: J Infect. 2006 Dec;53(6):357-63
references.pmid: 16487593
references.citation: AIDS. 2005 Jul 1;19(10):1043-9
references.pmid: 15958835
references.citation: Antivir Ther. 2005;10(5):615-24
references.pmid: 16152755
references.citation: Am J Respir Crit Care Med. 2007 Jan 1;175(1):87-93
references.pmid: 16973982
references.citation: Arch Intern Med. 2003 Oct 13;163(18):2187-95
references.pmid: 14557216
references.citation: AIDS. 2007 Mar 30;21(6):713-9
references.pmid: 17413692
references.citation: S Afr Med J. 2006 Aug;96(8):722-4
references.pmid: 17019496
references.citation: AIDS. 2007 Nov 30;21(18):2483-91
references.pmid: 18025885
references.citation: J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):14-7
references.pmid: 15608518
references.citation: AIDS. 2004 Apr 9;18(6):887-95
references.pmid: 15060436
references.citation: Lancet. 2006 Apr 15;367(9518):1256-61
references.pmid: 16631881
references.citation: PLoS Med. 2006 Jan;3(1):e4
references.pmid: 16318413
references.citation: Clin Infect Dis. 2007 Jul 1;45(1):76-80
references.pmid: 17554704
references.citation: Bull World Health Organ. 2004 May;82(5):354-63
references.pmid: 15298226
references.citation: J Infect Dis. 2005 Mar 15;191(6):825-9
references.pmid: 15717255
references.citation: AIDS. 1993 Dec;7(12):1569-79
references.pmid: 7904450
references.citation: AIDS. 2005 Dec 2;19(18):2141-8
references.pmid: 16284464
references.citation: AIDS. 2004 May 21;18(8):1159-68
references.pmid: 15166531
references.citation: Lancet. 2002 Jul 6;360(9326):34-40
references.pmid: 12114039
references.citation: AIDS. 2007 Jan 2;21(1):121-2
references.pmid: 17148984
references.citation: J Acquir Immune Defic Syndr. 2006 May;42(1):29-35
references.pmid: 16763490
references.citation: Lancet. 2006 Apr 22;367(9519):1335-42
references.pmid: 16631912
references.citation: AIDS. 2002 Jan 4;16(1):75-83
references.pmid: 11741165
references.citation: AIDS. 2007 Jun 19;21(10):1301-8
references.pmid: 17545706
references.citation: JAMA. 2006 Aug 16;296(7):782-93
references.pmid: 16905784
references.citation: BMJ. 1994 Jun 11;308(6943):1531-3
references.pmid: 7912597
references.citation: AIDS. 2006 Nov 28;20(18):2355-60
references.pmid: 17117022
references.citation: AIDS. 2008 Apr 23;22(7):873-82
references.pmid: 18427206
references.citation: AIDS. 2005 Aug 12;19(12):1243-9
references.pmid: 16052078
references.citation: J Adv Nurs. 2006 Apr;54(1):132
references.pmid: 16553698
references.citation: AIDS. 2007 Jan 30;21(3):335-41
references.pmid: 17255740
references.citation: Clin Infect Dis. 2005 May 15;40(10):1500-7
references.pmid: 15844073
references.citation: J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):320-3
references.pmid: 15076249
references.citation: J Acquir Immune Defic Syndr. 2002 Sep 1;31(1):20-6
references.pmid: 12352146
references.citation: J Acquir Immune Defic Syndr. 2006 Sep;43(1):78-84
references.pmid: 16878045
references.citation: J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):121-3; author reply 123
references.pmid: 17909319
references.citation: AIDS. 2006 Aug 1;20(12):1605-12
references.pmid: 16868441
references.citation: Lancet. 2006 Jun 3;367(9525):1870-2
references.pmid: 16753490
references.citation: Antivir Ther. 2003 Oct;8(5):385-93
references.pmid: 14640385
references.citation: Lancet Infect Dis. 2005 Jun;5(6):361-73
references.pmid: 15919622
references.citation: East Afr Med J. 1996 May;73(5 Suppl):S7-8
references.pmid: 8756018
references.citation: J Infect Dis. 2007 Aug 15;196 Suppl 1:S46-51
references.pmid: 17624825
references.citation: J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):336-43
references.pmid: 16249709
references.citation: S Afr Med J. 2007 Jun;97(6):412, 414-5
references.pmid: 17691468
references.citation: AIDS. 2003 Jun 13;17(9):1369-75
references.pmid: 12799558
references.citation: J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):56-61
references.pmid: 17972365
references.citation: J Infect Dis. 2004 Nov 1;190(9):1670-6
references.pmid: 15478074
references.citation: AIDS. 2003 Mar 7;17(4):575-84
references.pmid: 12598778
references.citation: BMC Infect Dis. 2006 Sep 01;6:136
references.pmid: 16948852
references.citation: Antivir Ther. 2006;11(1):63-72
references.pmid: 16518961
references.citation: Lancet. 2006 Oct 7;368(9543):1254-9
references.pmid: 17027731
references.citation: J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):626-31
references.pmid: 16044018